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Background: Patients with cystic fibrosis (CF) complicated by allergic bronchopulmonary aspergillosis (ABPA) are
vitamin D deficient and in vitro treatment with 1,25 (OH)2 vitamin D3 of CD4+ cells from CF patients with ABPA
decreases Aspergillus fumigatus(Af)-induced Th2 responses. This Phase I clinical trial investigated the safety and
effectiveness of daily vitamin D3 supplementation in CF patients with ABPA to reduce allergic responses and ABPA
symptoms, and increase serum vitamin D levels.
Methods: Seven patients ages 12 years and older with a clinical diagnosis of CF and ABPA with current evidence of
Af sensitization received 4000 IU vitamin D3 (cholecalciferol) daily for 24 weeks. The primary outcome of the study
was safety followed by the Aspergillus induced IL-13 response in CD4+ T cells to test the hypothesis that vitamin D
supplementation is safe and reduces Aspergillus induced IL-13 responses in CD4+ T cells. Secondary outcomes included
total IgE, Aspergillus- specific IgE, vitamin D levels, FEV1, urinary calcium/creatinine ratio, and cytokine production by
Aspergillus-stimulated peripheral blood T cells.
Results: Six months of vitamin D3 supplementation resulted in significant increases in serum 25-(OH) vitamin D level,
and the treatment was well tolerated without evidence of vitamin D toxicity or hypercalcemia. There were no serious
adverse events. Daily vitamin D supplementation led to significantly decreased Aspergillus induced IL-13 responses
between the baseline visit and that at 24 weeks (p = 0.04). Aspergillus-specific IgE level was also significantly decreased
after 8 (p = 0.035) and 24 weeks of daily vitamin D supplementation (p = 0.04).
Conclusions: 4000 IU vitamin D3 daily over a 24-week period is well tolerated in CF patients with a history ABPA and
current evidence of Th2 immunity to Af. . Daily vitamin D supplementation was associated with reduced Aspergillus
induced IL-13 responses from peripheral. . CD4+ T cells and Aspergillus-specific IgE levels, as well as increased
serum vitamin D levels. This treatment was well tolerated and the study supports further investigation of the use of
vitamin D supplementation in Th2 mediated diseases.
Trial registration: This trial was registered at www.clinicaltrials.gov as NCT01222273.
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Cystic fibrosis (CF) is the most common severely life-
shortening genetic disease in people of mixed European
descent, with lower prevalence in Hispanics, African
Americans, and Asians. Due to impaired mucociliary clear-
ance, CF patients are susceptible to fungal colonization in
the lungs, as up to 50 % of patients culture fungus from re-
spiratory secretions [1]. The most common fungal patho-
gen infecting CF patients is Aspergillus fumigatus. In one
study, a striking 84 % of CF patients had Aspergillus
fumigatus-specific IgG (Asp IgG) antibodies compared to
6 % in control subjects and 20 % in allergic asthmatics [2].
While an extremely high percentage of CF patients have ex-
posure to A. fumigatus, this may or may not result in clin-
ical disease. Impaired clearance of Aspergillus fumigatus in
the respiratory tract of immunocompromised individuals
can lead to clinical manifestations that include invasive
aspergillosis, mycetoma, fungal bronchitis, or allergic
bronchopulmonary aspergillosis (ABPA) [3]. In contrast to
patients with clinically irrelevant colonization and other
types of fungal disease, patients with CF and ABPA have al-
lergic immunological responses to Aspergillus fumigatus
antigens, which results in increased Th2 responses and in-
creased IgE levels [4, 5].
Vitamin D deficiency is prevalent in the CF population
due to inadequate absorption, impaired metabolism, and
limited sun exposure [6]. We have previously shown that
patients in our CF center with CF and ABPA have sig-
nificantly lower vitamin D levels than CF patients who
do not have ABPA [7]. Further, in vitro treatment with
1,25 (OH)2 vitamin D3 decreased Aspergillus induced IL-
13 responses from CD4+ T cells from ABPA patients [7].
In addition, it has been shown that a single, oral bolus of
cholecalciferol (25,000 IU) increased serum-25 (OH)
vitamin D concentrations and was associated with im-
proved clinical outcomes in CF patients hospitalized
with pulmonary exacerbations [8]. Further, a large, single
dose of vitamin D (25,000 IU) in CF patients during pul-
monary exacerbations was associated with a decrease in
the inflammatory cytokines IL-6 and TNFα [9]. Taken
together, these observations suggest that vitamin D plays
a critical role in modulating immune responses. We
therefore performed a Phase I, open label study to deter-
mine whether in CF patients with ABPA daily supple-
mental vitamin D is safe and reduces allergic response to
A. fumigatus. Based on our prior work, we chose the
Aspergillus specific IL-13 response as our primary im-
munologic outcome [7].
Methods
Study population
Subjects with CF with a prior history of clinically diag-
nosed ABPA were accrued from the Antonio J. and Janet
Palumbo Cystic Fibrosis Center at the University ofPittsburgh Medical Center into the 24-week clinical trial
of vitamin D supplementation (NCT01222273). To be
enrolled into the study, subjects had to be 12 years and
older, and have a diagnosis of CF based on standard cri-
teria. In addition, subjects had to be clinically diagnosed
with ABPA by a past or present respiratory culture for
A. fumigatus, and have either a current IgE greater than
250 IU/ml or an Aspergillus specific-IgE (Asp IgE) classi-
fied as Class II or higher. Detailed inclusion and exclu-
sion criteria are listed in Table 1. After meeting
enrollment criteria at the screening visit, patients began
the 24-week clinical trial of daily vitamin D supplemen-
tation with 4000 IU of vitamin D3 (cholecalciferol). Dur-
ing the trial, study subjects were seen 8 weeks (±7 days)
and 24 weeks (±7 days) after beginning drug treatment.
On the basis of our prior findings [7], we designed this
Phase I clinical trial to determine whether vitamin D
supplementation is safe and reduces allergic responses
to Aspergillus in CF patients with ABPA. Our primary
outcome was thus safety, followed by the Aspergillus-
induced IL-13 response in CD4+ T cells. Secondary out-
comes included total IgE, Aspergillus-specific IgE, vitamin
D level, FEV1, and cytokine production by Aspergillus-
stimulated peripheral blood T cells. Clinical assessments at
each time point are listed in Table 2.
The Institutional Review Board at the University of
Pittsburgh approved the trial, and patients provided
written informed consent and were enrolled in the trial
by one of the primary investigators.
Vitamin D supplementation
After meeting enrollment criteria, patients were given
the study drug. Vitamin D3 (cholecalciferol) was dis-
pensed as 1000 IU tablets, and patients were instructed
to take four tablets daily.
Cell harvest
Human CD4+ and CD11c + cells were obtained from
whole blood using Vacutainer CPT tubes (BD Pharmingen,
Franklin Lakes, NJ) and re-suspended in cell buffer com-
prised of EDTA (Gibco, Grand Island, NY), BSA (Sigma, St.
Louis, MO), and 1X PBS (Fisher, Waltham, MA). All cells
were isolated by magnetic bead activated sorting using
microbeads and MidiMacs (Miltenyi, Auburn, CA). The
CD4+ cells were first isolated by positive separation in MS
columns using CD4 Microbeads (Miltenyi). CD11c + cells
were subsequently isolated from the negative fraction of the
CD4+ isolation using Anti APC Microbeads then CD11c-
APC microbeads for the final magnetic separation. DCs
were then plated in flat bottom 96 well plates at a density
of 5×105 and 5×104 DC cells per well in medium contain-
ing RPMI, L-glutamine, pen strep, FBS (Gibco), and
Human AB serum (Atlanta Biologicals, Lawrenceville,
GA). Cells in the plate were then stimulated with the
Table 1 Inclusion and exclusion criteria for vitamin D supplementation trial
Inclusion criteria Exclusion criteria
● ≥12 years male or female ● Systemic corticosteroids (1 mg/kg if <20 kg or >20 mg of prednisone per day)
● Confirmed CF diagnosis
1. One or more clinical features consistent with CF phenotype
AND (2 or 3)
● Investigational drug use within 30 days of screening
2. Positive sweat chloride >60 mEq/L ● Laboratory abnormalities at screening
3. Two identifiable mutations consistent with CF ● Serum calcium > 11 mg/dL
● Written informed consent (or assent) ● 25 (OH) D > 50 ng/mL at screening
● Clinically stable at enrollment as assessed by site investigator ● Creatinine≥ 1.5 or estimated GFR < 60 by Cockcroft-Gault or MDRD equation
● Past or present respiratory culture positive for Aspergillus
fumigatus
● LFT≥ 3x ULN
● IgE≥ 250 and/or presence of Class II or higher Aspergillus specific
IgE on enrollment
● History or transplantation or currently on transplant list
● Ability to comply with medication use, study visits and study
procedures as judged by site investigator
● Positive serum pregnancy test at screening
● Pregnant, breastfeeding, or if post-menarche female, unwilling to practice
birth control during participation in study
● Presence of a condition or abnormality that would compromise safety of
subject or quality of data
● Diagnosis of HIV and a CD4+ T cell count < 500 cells/mL or active hepatitis
C infection
● Undergoing therapy for non-tuberculosis mycobacterial infection
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Minneapolis, MN) and/or Aspergillus extract (ASPEXT,
1 μg/ml) (Holister-stier, Spokane, WA). One well in the
plate was left un-stimulated as a control. 5×105 CD4+ cells
were then added. Control wells received CD4+ T-cells that
were cultured in media or stimulated with CD3/CD28
beads (Dynal/Invitrogen, Grand Island, NY). Additionally,
recombinant IL-2 was added to all wells on the plateTable 2 Timeline of clinical trial visits and assessments
Timepoint
Assessment Screening Visit 1
Day-7 to 28 Day 0
Informed consent x
Demographics/Medical history x
Concominant medications x x
Abbreviated physical exam x
Vital signs x x
Spirametry x
Clinical laboratory assessments x
Blood collection for CF genotype x
Blood collection for HLA typing x
Blood for banking (immune monitoring) x
Adverse event assessments x
Medication and diary drug x
Review study drug count and diary(7.5 ng/ml). Medium containing RPMI, 5 % L-glutamine,
5 % pen strep, 10 % FBS (Gibco), and 5 % Human AB
serum (Atlanta Biologicals) was then added to each well to
reach final volume. All cells were then incubated at 37 °C
and 5 % CO2 for 96 h. In some experiments, anti-human
IL-10 (1 μg/ml final concentration) or recombinant
human TGF-B sRII Fc Chimera (10 μg/ml final concentra-
tion) were added.Visit 2 Phone call Visit 3 Follow-up visit
Day 55 ± 7 Day 112 ± 7 Day 182 ± 7 Day 196 ± 7
x x x x
x x
x x
x
x
x
x x x x
x x
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IL-4, IL-5, IL-10, IL-13, and IL-17 were measured by
Luminex (Millipore, Billerica, MA) according to manufac-
turer’s instructions. The data was analyzed with Bio-Plex
Manager software (Bio-Rad, Hercules, CA). To control for
percentage of Aspergillus specific CD4+ T-cell in periph-
eral blood we normalized the APSEXT response to the
CD3/CD8 stimulated response as this represents the max-
imal cytokine response in the culture system.
Clinical laboratory assessment
Serum was collected and 25-OH vitamin D, IgE, Asp
IgE, and calcium levels were determined by Sunquest
Clinical Labs. Baseline total IgE and Asp IgE levels are
reported from the screening visit. In addition, we mea-
sured Ca, Phosphorous, ALT, AST, total bilirubin, alka-
line phosphatase, BUN, Cr, serum HCG, and IgG in all
or a subset of the study participants. Urinary calcium
and creatinine were measured at each time point and
urinary calcium:creatinine ratio was calculated to assess
for potential hypercalciuria (an early sign of vitamin D
toxicity).
Lung function
Lung function was measured using standard pulmonary
function tests according to American Thoracic Society
guidelines. Forced expiratory volume in 1 s (FEV1) was
measured and the percent of predicted FEV1 (FEV1 %
predicted) was calculated based on patient’s age and
height using NHANES-3 reference values 25.
Statistical analysis
All statistical analyses were performed using a one-tailed
paired T-test or one-way ANOVA with Prism software
(GraphPad).
Results
Seven ABPA patients completed all time points in the
study. The main characteristics of these subjects are
shown in Table 3. There were nearly equal numbers of
males and females, and study participants had the most
common CF genotypes.Table 3 Demographics of patients enrolled in vitamin D
supplementation trial
Measurement Value
BMI 22.5 ± 10.68 (17.25–30.75)
Age (years) 21.91 ± 2.69 (13.10–30.83)
Sex 4 female; 3 male
IgE (IU/mL) 344.6 ± 284.9 (142–835)
Asp IgE (kUA/I) 18.4 ± 14.7 (4.24–37.5)
Genotype ΔF508/R553X; ΔF508/612+ 1G-T; neg/ΔF508; ΔF508/
ΔF508; MEG/G542X; ΔF508/1213delT; ΔF508/R1162XVitamin D supplementation in CF patients with ABPA is
well tolerated and safe
At the initial screening visit, study participants had serum
vitamin D (25-OH vitamin D) concentrations of 35.86 ±
3.02 ng/mL (Fig. 1). After 8 weeks of daily supplementa-
tion with 4000 IU of vitamin D, serum 25-OH vitamin D
concentrations increased to 45.00 ± 6.09 ng/mL. At the
end of the 24-week trial, serum 25-OH vitamin D concen-
trations were significantly increased to 44.86 ± 3.262 ng/
mL (Fig. 1). A compliance table is listed as Table 4. Serum
calcium levels did not change significantly over the 24-
week trial period (Fig. 1), with average calcium levels of
9.41 ± 0.116 mg/dL at baseline and 9.59 ± 0.142 mg/dL at
24-weeks (Fig. 1). There was a statistically significant in-
crease in urinary calcium/creatinine ratios with an in-
crease in 3 of 7 patients over the 24-week trial period
(Fig. 1) but these increments were not associated with
any symptoms. There were also no serious adverse
events reported, indicating this vitamin D supplementa-
tion is safe and well tolerated.
Effect of vitamin D supplementation on aspergillus-induced
IL-13 responses
We next determined whether vitamin D supplementa-
tion affected Aspergillus induced IL-13 responses in per-
ipheral CD4+ T cells. At each time point in the vitamin
D supplementation trial, peripheral blood was drawn
and CD4+ T cells and CD11c + DCs were isolated by
magnetic separation. CD11c + DCs were pulsed with A.
fumigatus extract (ASPEXT), and CD4+ T cells were
added and cultured for 96 h. In addition, some cells were
cultured with TGFβ blocker or anti-IL10. To measure the
maximal T-cell response, co-cultures were stimulated with
human T-cell activating CD3/CD28 beads. Between the
baseline visit and 8 weeks after daily cholecalciferol sup-
plementation, there was a slight but statistically insignifi-
cant decrease in Th2 cytokine response to stimulation
with ASPEXT measured by IL-13 cytokine response
(Fig. 2). However, after 24 weeks on daily cholecalcif-
erol, patients showed a significant decrease in IL-13 re-
sponses to ASPEXT (Fig. 2).
We have also previously shown that stimulating
CD11c + DCs with TSLP increases Th2 response to A.
fumigatus in CF patients with ABPA via upregulation
of OX40L [10]. After 24 but not 8 weeks of vitamin
D supplementation, TSLP-CD11c + DCs, co-cultured
with autologous CD4+ T cells, also showed a signi-
ficant reduction in the A. fumigatus IL-13 response
(Fig. 2).
We have previously shown that in vitro 1,25 (OH)2
vitamin D3 treatment increases Treg cells and the block-
ade of TGFβ but not the Treg cytokine IL-10 in vitro at-
tenuates the suppressive effects of 1,25 (OH)2 vitamin
D3 on Th2 cytokine responses to A. fumigatus antigens
Fig. 1 Vitamin D3 supplementation increases serum 25-OH vitamin D and does not impact serum calcium or lung function. a) Vitamin D levels in-
creased over the 24 weeks of supplementation but were only significantly higher between day 0 and the 24-week time point. b) Serum calcium
levels did not change significantly over the 24-week trial period. c) Urine calcium:creatinine ratios increased slightly over 24-weeks and were significantly
higher between day 0 and 24-weeks. Data is graphed as for each individual patient at each time point P
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IL-10 would have similar affects in reversing vitamin D-
mediated Th2 cytokine inhibition. To test this hypoth-
esis, CD11c + DCs were stimulated with or without
TSLP and pulsed with ASPEXT, followed by the additionTable 4 Compliance by pill count
ID Age Started drug Stopped drug # days Should have
taken
# dispensed
1 25 10/21/2010 4/6/2011 168 672 750
2 23 6/5/2011 12/9/2011 188 752 750
3 30 10/2/2010 4/27/2011 208 832 750
4 21 1/27/2012 7/25/2012 180 720 750
5 24 4/25/2012 10/3/2012 162 648 750
6 12 3/10/2011 8/17/2011 161 644 750
7 13 3/8/2011 9/12/2011 189 756 750of autologous CD4+ T cells. DC/T cell co-cultures were
then incubated with sTGF-βII/FC or neutralizing anti-
body to IL-10 to antagonize TGFβ or IL-10 activity, re-
spectively. Between baseline and 8 weeks, there was no
significant change in A. fumigatus specific Th2 response,# returned # taken Compliance by
pill count (%)
Vit D dose at enrollment
110 640 95 400 QD
2 748 99 400 QD
0 ? ? 400 QD
58 662 92 50,000 TIW
102 648 100 ABDEK 2/day plus vitamin D 1000
units and 400 units once daily
121 629 98 50,000 BIW
29 721 95 50,000 Qweek
Fig. 2 Vitamin D supplementation decreases Aspergillus induced IL-13 responses in CD4+ T cells. CD11c + DCs with from patients with confirmed
ABPA before (D0) and 8 and 24 weeks after 4000 IU cholecalciferol daily were treated with a) media or b) TSLP (5 ng/ml) and then pulsed with
Aspergillus extract. Purified CD4+ T-cells were added for 96 h. Supernatants were harvested and analyzed by Luminex for IL-13 production. Data
is graphed as a percentage of the stimulated response (CD3/CD28) for each individual patient at each time point
Nguyen et al. Asthma Research and Practice  (2015) 1:3 Page 6 of 10measured by IL-13, regardless of blockade of TGFβ or
IL-10 (Fig. 3). However, contrary to our previous find-
ings, after 24 weeks of vitamin D supplementation, A.
fumigatus specific Th2 responses measured by IL-13
were still significantly decreased when TGFβ was neu-
tralized (Fig. 3). This Th2 cytokine reduction after
24 weeks of vitamin D treatment occurred whether
CD11c + DCs were pulsed with or without TSLP which
is know to upregulate OX40L in CD11c + cells (Fig. 2).
Neutralization of IL-10 did not affect CD4+ T-cell IL-13
responses from CD11c + DCs but the diminution in IL-
13 responses (Fig. 3) in TSLP treated DCs failed to reach
statistical significance suggesting that IL-10 may be play-
ing a role in the observed reduced Th2 responses using
these DCs (Fig. 3).
Effect of vitamin D supplementation on secondary
outcomes
We have previously shown that our ABPA patients have
high Aspergillus specific IgE and total IgE levels, which
was associated with lower serum vitamin D levels [7]. In
other allergic Th2-mediated diseases such as asthma,
lower vitamin D levels have been shown to be associated
with increased IgE levels and increased Aspergillus spe-
cific IgE levels [11, 12]. These data along with our own
support the treatment of Th2-mediated diseases with vita-
min D therapy. In our clinical trial, CF patients with ABPA
had average total IgE levels of 344.6 ± 107.7 (standard
error) IU/mL at the time of enrollment (Fig. 4). Total IgE
levels decreased only slightly to 312.6 ± 77.66 IU/mL at
the 24-week ending time point (Fig. 4). While total IgE
levels did not significantly decrease, Aspergillus-specific
IgE levels showed a significant reduction over the 24-week
clinical trial period. At baseline, Asp IgE levels were
16.04 ± 5.594 kUA/I and significantly decreased to 14.03 ±
6.011 at 8 weeks after beginning daily cholecalciferolsupplementation (Fig. 4). By the end of the 24-week
clinical trial period, Asp IgE levels significantly de-
creased to 11.73 ± 3.581 (Fig. 4). Further, there were no
significant changes in lung function measured by forced
expiratory volume in 1 s in total FEV1 or FEV1 % predic-
ted (data not shown).
Finally, we also assessed Aspergillus stimulated IL-5
responses from peripheral CD4 + T cells. Between the
baseline visit and 8 weeks after daily cholecalciferol sup-
plementation, there was a statistically insignificant de-
crease in antigen stimulated IL-5 cytokine responses
(Fig 5). However, after 24 weeks on daily cholecalciferol, pa-
tients showed a significant decrease in IL-5 responses to
ASPEXT (Fig. 5). This reduction in IL-5 was also main-
tained when TSLP activated DCs were added to the culture
(Fig. 5).
Discussion
In most individuals, when benign antigens are inhaled,
the lung responds with a tolerogenic immunological re-
sponse [13–15]. However, in diseases such as ABPA, tol-
erance is lost or not established, and patients become
sensitized to the inhaled fungal antigen Aspergillus fumi-
gatus. We have previously shown that peripheral CD11c +
DCs and TSLP-DCs from ABPA patients induce robust
Th2 cytokine responses from autologous CD4+ T-cells in
an OX40L-dependent manner [7]. In addition, in our CF
cohort, vitamin D deficiency was associated with ABPA.
In vitro treatment with 1,25-(OH)2 vitamin D3 reduced
the robust Th2 response in patients with ABPA [7]. Based
on data from our observational study, we initiated a clin-
ical trial to assess the safety and the immunological effects
of supplemental vitamin D3 (cholecalciferol) in patients
with CF and ABPA.
This Phase I trial was implemented to test the safety and
efficacy of vitamin D supplementation in CF patients with
Fig. 4 Effect of vitamin D on IgE and Aspergillus specific IgE. Daily vitamin D supplementation did not affect total IgE levels over a 24 week
period (a) but vitamin D treatment significantly decreased Aspergillus specific IgE over 8 weeks and 24 weeks (b)
Fig. 3 Blockade of TGFβ or IL-10 signaling does not reverse vitamin D mediated IL-13 cytokine production. CD11c + DCs with from patients with
confirmed ABPA before (D0) and after supplementation with 4000 IU cholecalciferol daily were treated with a and c) media or b and d) TSLP
(5 ng/ml) and then pulsed with Aspergillus Extract followed by addition of allogeneic bulk CD4+ T-cells followed by addition of a and b) sTGF-βII/FC
(10 μg/mL) or c and d) anti-IL-10 (1 μg/mL). Cells were incubated for 96 h and IL-13 was measured in cell supernatants by Luminex. Data is graphed as
a percentage of the stimulated response (CD3/CD28) for each individual patient at each time point
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Fig. 5 Vitamin D supplementation decreases A. fumigatus specific Th2 response. CD11c + DCs with from patients with confirmed ABPA before
and 8 and 24 weeks after supplementation with 4000 IU cholecalciferol daily (n = 7) were treated with a) media or b) TSLP (5 ng/ml) and then pulsed
with Aspergillus Extract. Purified CD4+ T-cells were added for 96 h. Supernatants were harvested and analyzed by Luminex for IL-5 production. Data is
graphed as a percentage of the stimulated response (CD3/CD28) for each individual patient at each time point)
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perspective, the addition of daily vitamin D supplementa-
tion of 4000 IU significantly increased serum 25-OH vita-
min D levels without vitamin D toxicity or hypercalcemia
over the 24-week clinical trial period in CF patients with
ABPA. It is important to note that this dose of vitamin D
was prescribed on top of the patients regular vitamin D
schedule (Table 4). Vitamin D dosing has moved beyond
the typical 400 IU per day (Table 1) and this may explain
why baseline vitamin D levels were higher in this cohort
than our prior study [7]. As further evidence of compli-
ance urine calcium:creatinine ratios increased to above 0.2
in 3 out of 7 patients at the 24-week time point. Typically,
ratios above 0.2 may be indicative of hypercalciuria [16].
However, urine samples were collected at random during
clinic visits. A 24-h urine collection would be more accur-
ate at determining urine calcium excretion in our patients
[16, 17]. After 24 weeks on daily vitamin D supplementa-
tion, patients had 25-OH vitamin D levels of 44.86 ±
8.630 ng/mL. These values are considered to be slightly
above the minimal threshold (>30 ng/mL) of preferred 25-
OH vitamin D concentrations recommended by the Cystic
Fibrosis Foundation (CFF) [18].
The primary immunological outcome measure was the
A. fumigatus specific IL-13 response in peripheral CD4+
T-cells. Over the 24-week period, IL-13 responses to A.
fumigatus from DC/T-cell co-cultures significantly de-
creased. We have previously shown that in vitro 1,25-
(OH)2 vitamin D3 increased CD4 +CD25 + TGFβ +Tregs
[7] and others have shown that in vitro 1,25 dihydroxyvita-
min D3 synergized to increase IL-10 in Tregs [19]. How-
ever, in this vitamin D supplementation study, blockade of
TGFβ or IL-10 did not reverse inhibitory effects of vitamin
D, suggesting that the decreased Th2 response in periph-
eral CD4+ T-cells after 24-weeks of vitamin D is not
dependent on TGFβ or IL-10 in the ex vivo culture. We
did not assess the frequency of FoxP3+ CD4+ T-cells inperipheral blood in this study and thus we cannot exclude
an affect of vitamin D on the in vivo Treg population. It
was recently shown that 1,25-(OH)2 vitamin D3 increased
the expression the anti-microbial peptide LL-37 in CF epi-
thelial cells along with decreasing inflammatory cytokines
[20, 21]. LL-37 has been shown to have antimicrobial ac-
tivity against microbes as well as fungi and viruses [22]
and it has immunomodulatory effects on both epithelial
cells and dendritic cell differentiation [23]. In addition to
decreasing Th2 responses, one explanation for the de-
creased response to A. fumigatus with vitamin D supple-
mentation may be due to an increase in antimicrobial
peptides such as LL-37. While our clinical study had only
7 CF patients with ABPA who completed the 24-week
vitamin D supplementation trial, we demonstrated that
vitamin D supplementation reduced A. fumigatus specific
IL-13 responses.
There are several limitations to the current study.
First, prior to this vitamin D supplementation trial, the
guidelines for 25-OH vitamin D concentrations were
modified by the CFF. This may have contributed to the
baseline Vitamin D levels being higher in this cohort
prior to supplementation particularly in comparison to
25-OH vitamin D levels of 26.80 ± 15.32 ng/mL than in
the initial observational study7, which were well below
the current clinically recommended serum concentra-
tions [18]. This may have limited our ability to detect an
immunomodulatory effect of Vitamin D on Aspergillus
responses. Despite the higher mean vitamin D levels in
this cohort, Aspergillus-specific IgE levels decreased over
the 24-week period. Second, the limited size of the study
population did not permit us to track changes in other
therapies for ABPA, such as prednisone and antifungal
use that may have affected lung function and in vitro re-
sponses. Further studies are necessary to clarify this.
Others have shown that vitamin D deficiency is sig-
nificantly and inversely associated with total IgE and
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lus colonization itself has been shown to impair vita-
min D receptor expression in CF [25]. Furthermore a
recent clinical trial of vitamin D in asthma patients
who were vitamin D deficient was negative in terms of
vitamin D supplementation reducing time to first ex-
acerbation or affecting FEV1 [26]. However Th2 im-
munity was not assessed as part of this trial. Moreover
there was only measure of serum vitamin D levels
which may not accurately measure VDR function which
can be regulated by Aspergillus [25]. There is evidence
that we impacted VDR function in this trial as mea-
sured by the increase in the urine calcium:creatinine
ratio.
Conclusions
Taken together with the results from this Phase I study,
vitamin D supplementation may be beneficial in decreas-
ing these allergic responses. These data provide rationale
for increased vitamin D supplementation of CF patients
with ABPA in addition to supporting further study of
the effects of vitamin D supplementation to treat or
prevent ABPA. Moreover fungal specific IL-13 responses
may be a useful biomarker for future studies in patients
with ABPA.
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